Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/09/22
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 01/24/24
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | NCT05266612 | Virogin Biotech Canada Ltd | user2@example.com | None | 2022-11-09 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | NCT05223816 | Virogin Biotech Canada Ltd | user2@example.com | None | 2024-01-24 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |